From WIRED · Javier Carbajal · · 1m 20s
Smart nanoparticles flip immune cells to fight cancer
New mRNA therapy targets tumor-protecting cells and turns them back into cancer fighters.
In brief
New mRNA therapy targets tumor-protecting cells and turns them back into cancer fighters. Researchers developed targeted nanoparticles that deliver mRNA directly to tumor sites, reprogramming immune-suppressing cells to attack cancer instead. Originally reported by WIRED.
Tumors hijack immune cells
Cancer cells create an environment that reprograms immune cells to suppress the body's defenses. Tumor-associated macrophages block T cells from attacking the tumor.
“The tumor environment can stop those immune cells from doing their job”
mRNA carries reprogramming instructions
The therapy uses mRNA to instruct hijacked macrophages to produce CXCL9, a signal that recruits cancer-fighting T cells. The challenge is delivering it safely to the right place.
Smart nanoparticles target specific cells
Researchers coated nanoparticles with antibodies that bind to TREM2, a protein only on tumor-associated macrophages. This ensures the mRNA reaches only cells that need reprogramming.
Lab results show dramatic changes
Treated macrophages began producing CXCL9 and other immune activation markers. Expression of NOS2 increased by a factor of 89.5 while immunosuppressive signals dropped.
Mice with breast cancer responded
After three doses, tumor growth slowed and CXCL9 levels quadrupled. The treatment reduced immunosuppressive macrophages by 63 percent and activated T cells at the tumor site.
Human trials still years away
Combining the therapy with existing immunotherapies increased T cell populations in tumors. No organ damage was detected, but extensive safety studies are needed before testing in people.
“This is an important proof of concept that we can use mRNA and nanoparticle technology to reprogram the immune environment of a tumor”
What it means
Researchers developed targeted nanoparticles that deliver mRNA directly to tumor sites, reprogramming immune-suppressing cells to attack cancer instead.
